GE HealthCare’s Allia Moveo Cleared by FDA and CE Marked, Bringing AI-Driven Imaging to the Interventional Suite

GE HealthCare (Nasdaq: GEHC) announced that its latest innovation, Allia™ Moveo, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking. This marks a significant milestone for the company's interventional imaging portfolio. First introduced at the 2025 Radiological Society of North America (RSNA) Annual Meeting, Allia Moveo is designed to bring enhanced mobility, precision, and efficiency to the interventional suite. It supports a wide variety of procedures in cardiovascular, vascular, non-vascular, interventional, and surgical care settings.

Allia Moveo introduces a compact, cable-free C-arm system with an intuitive user interface and artificial intelligence-powered guidance tools, allowing clinicians to work more efficiently in environments where space is limited. The system is intended to address spatial and workflow constraints commonly faced in traditional interventional rooms.

The first global installation was completed at Hôpital Marie-Lannelongue in France, a leading center in thoracic, vascular, and cardiac surgery, and a national reference site for complex aortic pathology. The hospital is now using Allia Moveo for flexible cone-beam computed tomography imaging to support treatment of vascular and cardiology conditions. The system features a wide-bore design and smooth table panning to accommodate a broad range of patient body types while ensuring ease of access and comfort during procedures.

Dr. Stephan Haulon, Vascular Surgeon and Head of the Aortic Center and Vascular Surgery at Hôpital Marie-Lannelongue, praised the system's flexibility and image quality. He noted that the AI-driven CleaRecon DL feature offers superior cone beam CT image reconstruction, adapting quickly to optimal working positions for the clinical team.

As interventional procedures become more complex, there is a growing need for imaging solutions that enhance clinical insight, support fast and easy positioning, and deliver high-quality imaging while integrating seamlessly with other systems—all in an environment quieter than a typical conversation. GE HealthCare developed Allia Moveo in direct collaboration with clinicians to address these evolving demands. The system is designed to be intuitive and fluid in operation, allowing providers to maintain control and improve workflow efficiency.

Arnaud Marie, General Manager of Interventional Solutions at GE HealthCare, emphasized the impact of Allia Moveo in enhancing the clinical experience. He stated that this launch is a significant step forward for care teams and their patients, removing procedural complexity and providing clinicians with greater control and faster access to critical insights.

The Allia Moveo platform incorporates advanced 3D imaging capabilities to support precise clinical decision-making. These include CleaRecon DL, an AI-based reconstruction tool that reduces streak artifacts from pulsatile blood flow to provide clearer images; Motion Freeze, which minimizes respiratory motion artifacts to improve image clarity; and Metallic Artifact Reduction, developed to reveal anatomical details often obscured by metal. The system also supports augmented guidance applications through GE HealthCare’s ASSIST portfolio and is compatible with both GE and third-party technologies.

Following the system’s first installation in France, Baylor St. Luke’s Medical Center in Houston, part of CommonSpirit Health, became the first U.S. hospital to implement the platform. Dr. Brad Lembcke, President of the medical center, expressed enthusiasm about adopting Allia Moveo, stating that the system improves navigation during complex minimally invasive procedures by enhancing mobility, image quality, and operational flow. He added that the platform strengthens the institution’s ability to deliver precise, patient-centered care with technology tailored to the demands of modern interventional medicine.